At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DNA Ginkgo Bioworks Holdings Inc.
Not Yet Opened 12-20 16:00:00 EST
10.08
+1.34
+15.33%
盘后10.06
-0.02-0.20%
19:43 EST
High10.53
Low8.40
Vol3.32M
Open8.46
D1 Closing8.74
Amplitude24.41%
Mkt Cap579.39M
Tradable Cap403.39M
Total Shares57.48M
T/O33.37M
T/O Rate8.30%
Tradable Shares40.02M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Applied DNA customer UHKT initiates Phase I clinical trial of UHKT-CAR123-01
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
Ginkgo Bioworks Awarded $9.4 Million in Partnership With Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under Arpa-H's React Program
Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.